IQVIA Holdings Inc at Barclays Global Healthcare Conference Transcript
Okay. Well, good afternoon. I'm Jack Meehan, the Barclays Life Science Tools & Diagnostics analyst. And in our first presentation in the afternoon, very pleased to have IQVIA CFO, Mike McDonnell.
(technical difficulty)
And we'll kick it off. So first, what do you view as IQVIA's organic growth profile over the next 3 years? Anybody can answer? This can be a little preview for the Analyst Day later in the year.(inaudible) mix of high-single digits followed by mid-single digits. And next question, do you expect organic growth to accelerate from current levels, let's say for 2019? So either no. And then if when starting in 2019 this year 2020 or 2021 and beyond?
(technical difficulty)
Expecting an acceleration. And then finally, capital deployment, how do you want to see Mike deploy capital in 2019? So M&A, repurchase, paying a dividend, repay debt or invest in the core?
(inaudible) So investing in the core followed by repurchase. So with that, Mike, let's hop right in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |